Biogen LEQEMBI Subcutaneous Starting Dose PDUFA July 25

Biogen (BIIB) and Eisai face a July 25 PDUFA date for their supplemental BLA seeking FDA approval of LEQEMBI IQLIK (lecanemab-irmb) as a subcutaneous starting dose for early Alzheimer’s disease. The application received Priority Review.

A PDUFA date is the FDA’s deadline to decide on a drug application. If the agency approves this sBLA, the subcutaneous autoinjector formulation could be used from the beginning of therapy, not just for maintenance dosing after 18 months of IV infusions. The injection takes roughly 15 seconds, compared with hour-long IV infusions that require a clinic visit.

What is already approved

LEQEMBI IQLIK is already FDA-approved as a subcutaneous maintenance dose for early Alzheimer’s patients who have completed 18 months of IV lecanemab. The current sBLA would extend SC administration to the starting-dose phase, potentially enabling at-home administration from day one. That convenience shift matters for an elderly population where travel to infusion centers imposes a real burden on patients and care partners.

The drug itself, lecanemab, is an anti-amyloid antibody that clears brain amyloid plaques. It was originally approved as IV Leqembi in January 2023, with the SC IQLIK formulation approved later. A starting-dose approval would complete the IV-to-SC transition.

Why subcutaneous matters here

Alzheimer’s patients face mobility, transportation, and caregiver-availability constraints that make biweekly IV clinic visits difficult. Moving the entire treatment course to a 15-second subcutaneous injection removes a major access barrier. It could also expand the addressable patient population to those who declined or discontinued IV infusions due to logistics.

Eli Lilly’s competing anti-amyloid therapy, Kisunla (donanemab), is IV-only. A full SC Leqembi would hold a convenience advantage over the only other approved disease-modifying Alzheimer’s drug. For more on how label expansions extend drug franchises, see our coverage of Madrigal’s resmetirom PDUFA.

Competitive context

Biogen stock closed at $200.62 on July 23, up from $197.04 at the open, on volume of 1.03 million shares. The stock has been under pressure amid broader Alzheimer’s drug class concerns. Guggenheim recently raised its price target to $280 from $260, maintaining a Buy.

The anti-amyloid space has struggled with safety concerns. LEQEMBI carries a warning for amyloid-related imaging abnormalities (ARIA), which include brain swelling and bleeding. Subcutaneous dosing does not eliminate this risk, and post-approval surveillance will be important for any label expansion.

What to watch next

The FDA decision on July 25. An approval would mark the final step in Leqembi’s IV-to-SC transition and give Biogen a convenience story against IV-only competitors. A delay or rejection would raise questions about the SC formulation’s safety profile during the starting-dose phase.

If approved, watch for payer coverage decisions and whether at-home administration gets reimbursement support. That will determine whether the convenience advantage translates into commercial uptake.

Eisai press release on FDA sBLA acceptance | Dansfera drug profile